• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[法国2型糖尿病患者开始胰岛素治疗的成本决定因素：优化的可能方法]

[Determinants of the cost of initiation of insulin therapy type 2 diabetic patients in France: possible approaches to optimization].

作者信息

Hanaire Hélène, Attali Claude, Lecointre Brigitte, Fraysse Martial, Gouet Didier, Babel Marie-Renée, Charbonnel Bernard, Sarkozy François, Gourmelen Julie, Detournay Bruno

出版信息

Sante Publique. 2016 Dec 19;28(6):781-789.

PMID:28155773
Abstract

Increased costs cannot be exclusively attributed to the consequences of insulin prescription. Any initiative designed to accelerate acquisition of patient autonomy would be likely to reduce the costs observed after switching to insulin, provided this initiative is adapted to the patient’s health profile, diabetes history and available medical resources..

摘要

成本增加不能完全归因于胰岛素处方的后果。任何旨在加速患者自主性获得的举措，只要该举措适合患者的健康状况、糖尿病病史和可用医疗资源，都可能降低改用胰岛素后所观察到的成本。

相似文献

1
[Determinants of the cost of initiation of insulin therapy type 2 diabetic patients in France: possible approaches to optimization].[法国2型糖尿病患者开始胰岛素治疗的成本决定因素：优化的可能方法]
Sante Publique. 2016 Dec 19;28(6):781-789.
2
Resource utilization with insulin pump therapy for type 2 diabetes mellitus.胰岛素泵治疗 2 型糖尿病的资源利用。
Am J Manag Care. 2010;16(12):892-6.
3
[Costs of antihyperglycemic treatment and consumables and treatment satisfaction in patients with type 2 diabetes].2型糖尿病患者的降糖治疗成本、耗材及治疗满意度
Dtsch Med Wochenschr. 2009 Nov;134(46):2355; author reply 2355-6. doi: 10.1055/s-0029-1242695. Epub 2009 Nov 5.
4
Increased healthcare utilization costs following initiation of insulin treatment in type 2 diabetes: A long-term follow-up in clinical practice.2型糖尿病患者开始胰岛素治疗后医疗费用增加：临床实践中的长期随访
Prim Care Diabetes. 2017 Apr;11(2):184-192. doi: 10.1016/j.pcd.2016.11.002. Epub 2016 Nov 25.
5
Comparing insulin vials to pens--comparison of charges, not healthcare benefits.胰岛素小瓶与笔式注射器的比较——费用比较，而非医疗效益比较。
J Med Econ. 2013 Oct;16(10):1228-30. doi: 10.3111/13696998.2013.832259. Epub 2013 Sep 5.
6
Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.在中国血糖控制不佳的2型糖尿病患者中转换为使用双相门冬胰岛素的成本效益分析
Adv Ther. 2008 Aug;25(8):752-74. doi: 10.1007/s12325-008-0080-4.
7
Effect of exenatide, pen insulin, and vial insulin on patient outcomes: a retrospective database analysis of persistence and first-year costs in a commercially insured population.艾塞那肽、笔芯胰岛素和瓶装胰岛素对患者结局的影响：商业保险人群中基于回顾性数据库的持久性和首年费用分析。
Clin Ther. 2012 May;34(5):1145-58. doi: 10.1016/j.clinthera.2012.02.030. Epub 2012 Mar 28.
8
Direct healthcare costs and clinical outcomes after insulin initiation in patients with type 2 diabetes mellitus in Spain: 24-month follow-up data from the INSTIGATE study.西班牙2型糖尿病患者起始胰岛素治疗后的直接医疗费用和临床结局：来自INSTIGATE研究的24个月随访数据
Endocrinol Nutr. 2013 May;60(5):224-34. doi: 10.1016/j.endonu.2012.11.010. Epub 2013 Mar 23.
9
Insulin therapy for diabetes mellitus: treatment regimens and associated costs.糖尿病的胰岛素治疗：治疗方案及相关费用。
Diabetes Metab. 2012 Apr;38(2):156-63. doi: 10.1016/j.diabet.2011.10.003. Epub 2011 Dec 14.
10
Cost-effectiveness of switching to biphasic insulin aspart 30 from human insulin in patients with poorly controlled type 2 diabetes in South Korea.在韩国，将血糖控制不佳的 2 型糖尿病患者的人胰岛素转换为双相胰岛素类似物门冬胰岛素 30 的成本效益分析。
Value Health. 2009 Nov-Dec;12 Suppl 3:S55-61. doi: 10.1111/j.1524-4733.2009.00628.x.

引用本文的文献

1
Treatment Costs of Basal Insulin Regimens for Type 2 Diabetes Mellitus in France.法国2型糖尿病基础胰岛素治疗方案的治疗成本
Pharmacoecon Open. 2021 Jun;5(2):211-219. doi: 10.1007/s41669-020-00237-4. Epub 2020 Nov 20.
2
Costs and its drivers for diabetes mellitus type 2 patients in France and Germany: a systematic review of economic studies.法国和德国2型糖尿病患者的成本及其驱动因素：经济研究的系统综述
BMC Health Serv Res. 2020 Nov 16;20(1):1043. doi: 10.1186/s12913-020-05897-w.
3
Costs and where to find them: identifying unit costs for health economic evaluations of diabetes in France, Germany and Italy.
成本及其来源：确定法国、德国和意大利糖尿病卫生经济评价的单位成本。
Eur J Health Econ. 2020 Nov;21(8):1179-1196. doi: 10.1007/s10198-020-01229-1. Epub 2020 Oct 6.
4
Cost of Managing Type 2 Diabetes Before and After Initiating Dipeptidyl Peptidase 4 Inhibitor Treatment: A Longitudinal Study Using a French Public Health Insurance Database.二肽基肽酶4抑制剂治疗前后2型糖尿病的管理成本：一项使用法国公共医疗保险数据库的纵向研究
Diabetes Ther. 2020 Feb;11(2):535-548. doi: 10.1007/s13300-020-00760-x. Epub 2020 Jan 17.